The limited efficacy of PD-1/PD-L1 blockade in PCa – despite the immune checkpoint inhibitors (ICI) therapy’s transformative impact on solid tumors – highlights the imperative to delineate PCa’s distinct immune evasion mechanisms. The gene discussed is PDCD1; the disease is posterior cortical atrophy.